FDA Stresses Need for Progressive Approach to Drug Development Regulation
August 2, 2022
Faced with an evolving clinical research and drug development landscape that was accelerated dramatically by COVID-19, the FDA’s Office of New Drugs (OND) will continue to take a progressive, adaptive approach to drug regulation going forward and explore innovative trial designs, according to its yearly report.